Table 4.

Baseline characteristics and clinical outcomes of patients taking only oral PPIs at baseline that were continued for >2 days compared with patients not prescribed PPIs during hospitalisation or at discharge, with patients diagnosed with suspected variceal bleed at baseline excluded.

	PPI at baseline	Non-PPI at baseline	P value
Baseline Clinical Characteristics
Number	272	281
Mean age, yrs (SD)	53.6 (11)	53.38 (10)	0.81
Male	197 (72.4%)	198 (71%)	0.70
Female	75 (27.6%)	87 (29.5%)	0.70
Alcohol	250 (91.9%)	248 (88.2%)	0.28
Alcoholic Hepatitis	76 (28.1%)	68 (24.2%)	0.37
Albumin treatment	130 (48.3%)	140 (49.8%)	0.55
NSBB use	69 (25.4%)	32 (11.4%)	2.28903E-05∗
Suspected Variceal Bleed	0	0
Ascites	182 (67.4%)	202 (69.6%)	0.18
Use of antibiotics	128 (47.1%)	126 (45.5%)	0.71
MELD Score median (95% CI)	19.47 (17.6–20.3)	19.88 (19–20.9)	0.06
Serum Albumin g/L -median (95% CI)	24 (23–24)	24 (23–24)	0.86
Creatinine mmol/L -median (95% CI)	68 (63–74)	66 (64–70)	0.22
WCC x109/L - median (95% CI)	7.4 (6.8–8)	8.2 (7.5–9)	0.0068∗
CRP mg/L - median (95% CI)	28 (23–32)	24 (21–29)	0.70
Bilirubin mg/L - median (95% CI)	85 (72–99)	111 (102–134)	0.0027∗
Primary Clinical Outcomes
Diagnosis of infection at randomization	78 (28.7%)	78 (27.8%)	0.87
Incidence of new infection (days 3–15)	49 (18.0)	50 (17.8%)	0.95
New infection reported as SBP	3 (1.1%)	5 (1.7%)	N/A
HE at randomization (all grades)	56 (20.7%)	45 (16%)	0.19
Incidence of new grade III/IV HE (days 3–15)	19 (7.0)	10 (3.6)	0.07
Incidence of new grade I/II HE (days 3–15)	23 (8.5%)	22 (7.8%)	0.79
Secondary Clinical Outcomes
Incidence of Kidney dysfunction	36 (13.2)	29 (10.3)	0.29
Incidence of death during hospitalisation	14 (5.1)	22 (7.8)	0.20
28-day mortality	36 (13.2)	38 (13.5)	0.92
90-day mortality	62 (22.8)	65 (23.1)	0.92
180-day mortality	84 (30.9)	92 (32.7)	0.64

∗P values < 0.05.